| Name | Title | Contact Details |
|---|
GBT is a clinical-stage biopharmaceutical company determined to discover, develop and deliver innovative treatments that provide hope to underserved patient communities. GBT is developing its late-stage product candidate, voxelotor (previously called GBT440), for the treatment of sickle cell disease.
Delinia has assembled a leadership team, Board of Directors and Scientific Advisory Board comprised of experienced investors, world-class academicians and industry veterans with proven track records for building exceptional life sciences companies.
SalioGen Therapeutics is advancing the Exact DNA Integration Technology (EDIT) platform, the only genome engineering technology that is mammal-derived, for use in potentially curative non-viral gene therapy.
Nutripro Biosystems, Inc is a Worthington, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Rapid, Personalized T-cell Therapies for Cancer on BlueSphere Bio…